Study Stopped
COVID-19
Human Plasma Fatty Acid Oscillations
Exploratory Phase I Study to Define Plasma Fatty Acid Oscillations in Patients With Night Eating Syndrome Compared to Healthy Volunteers.
1 other identifier
observational
12
1 country
1
Brief Summary
This study wishes to look at the 24-hour rhythm of certain fats in the blood stream. Recent studies in animals and healthy participants suggest that unusual eating habits may be connected to a change in the 24-hour rhythm of the blood fats the investigators wish to measure. The investigators will ask persons suffering from night eating syndrome, a condition where people eat additional meals throughout the night, to participate in this study. Healthy volunteers who are of the same age and gender, and have a comparable body-mass-index, a number calculated from a person's weight and height, will also be asked to participate. The aim is to learn how the 24-hour rhythm of the blood fats the investigators measure differs between the persons experiencing the night eating episodes and persons who do not.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jul 2015
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2015
CompletedFirst Submitted
Initial submission to the registry
July 2, 2015
CompletedFirst Posted
Study publicly available on registry
July 20, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2028
January 23, 2026
January 1, 2026
11.9 years
July 2, 2015
January 21, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Plasma fatty acids
\[% total fatty acid pool\]
64 hours
Secondary Outcomes (3)
Blood metabolite concentrations
64 hours
Core body temperature
64 hours
Bacterial taxa
64 hours
Study Arms (2)
Patients with Night-Eating Syndrome
Individuals diagnosed with Night Eating Syndrome (NES); 18-65 years of age; eating 30% of their caloric intake after dinner with nocturnal awakenings to eat at a frequency of ≥ 5 times per week
Matched Healthy Controls
Healthy volunteers; 18-65 years of age; eating \<25% of their caloric intake after dinner; no nocturnal ingestions
Interventions
Eligibility Criteria
Patients with Night-Eating Syndrome: Participants have to meet both of the criteria for nocturnal ingestions and evening hyperphagia; eat 30% of their caloric intake after dinner with nocturnal wake ups to eat at a frequency of ≥ 5 times per week. Matching healthy participants: Participantswill be matched to a patient with Night-Eating Syndrome by gender, age and BMI.
You may qualify if:
- Volunteers must be in good health as based on medical history, physical examination, vital signs, and laboratory tests as deemed by PI, BMI of 27-32;
- Volunteers are capable of giving informed consent;
- years of age;
- Non-smoking; and
- Non-pregnant, female subjects must consent to a urine pregnancy test.
- Control subjects eat less than 25% of their caloric intake after dinner without nocturnal ingestions;
- NES patients have to meet both of the criteria for nocturnal ingestions and evening hyperphagia; eat 30% of their caloric intake after dinner with nocturnal wake ups to eat at a frequency of ≥ 5 times per week
You may not qualify if:
- Recent travel across time zones (within the past month);
- Planned travel across time zones during the planned study activities;
- Volunteers with irregular work hours, e.g. night shifts or swing shift schedule;
- Subjects, who have received an experimental drug, used an experimental medical device within 30 days prior to screening, or who gave a blood donation of ≥ one pint within 8 weeks prior to screening;
- Subjects with any abnormal laboratory value or physical finding that according to the investigator may interfere with interpretation of the study results, be indicative of an underlying disease state, or compromise the safety of a potential subject;
- Diagnosis of severe depression, lifetime diagnosis of bipolar disorder or any psychotic disorder;
- Prescription and non-prescription (OTC) medication; medication with psychotropics (including hypnotics);
- Actively participating in a weight loss diet or program;
- Diagnosed with a different eating disorder; and lack of awareness of the night eating episodes (to differentiate from nocturnal sleep-related eating disorder, in which nocturnal eating is accompanied by a lack of awareness at the time and amnesia for the behavior the following day.)
- Subjects who have taken medications including antibiotics 2 weeks prior to the start of the study and throughout the study deemed by the investigator to interfere with the measurement of the study. Birth control pills are acceptable and will not be excluded;
- Subjects who have taken aspirin or aspirin containing products for the 2 weeks prior to the start of the study and throughout the study;
- Subjects who have taken acetaminophen, NSAIDS, COX-2 inhibitors (OTC or prescription) for 1 week prior to the start of the study and throughout the study;
- Subjects who are currently consuming any type of tobacco product(s);
- Use of recreational drugs within the last 6 months;
- Subjects who consume high doses of antioxidant vitamins daily (vitamin C \> 1000mg, Vitamin E \> 400 IU, Beta Carotene \> 1000IU, Vitamin A \> 5000IU, Selenium \> 200mcg, Folic Acid \> 1mg) for the 2 weeks prior to the start of the study and throughout the study;
- +12 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania, 19104, United States
Related Links
Biospecimen
Genetic analysis will be performed using High Throughput Sequencing (HTS) technology.
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Georgios Paschos, PhD
University of Pennsylvania
- PRINCIPAL INVESTIGATOR
Kelly C Allison, PhD
University of Pennsylvania
- PRINCIPAL INVESTIGATOR
Garret A FitzGerald, MD
University of Pennsylvania
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Research Assistant Professor
Study Record Dates
First Submitted
July 2, 2015
First Posted
July 20, 2015
Study Start
July 1, 2015
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
July 1, 2028
Last Updated
January 23, 2026
Record last verified: 2026-01